CANF Similar Chart Price Prediction
The price of CANF is predicted to go up -9.92%, based on the high correlation periods with SGMO. The similarity of these two price pattern on the periods is 96.13%.
CANF
SGMO
Down: -9.92%Similarity: 96.13%
CANF Revenue Forecast
CANF EPS Forecast
CANF Analyst's Forecast
Jason Kolbert
D. Boral Capital
Strong Buy
2024-12-31
Price Target
$10
Upside
+515.38%
D. Boral Capital notes that Can-Fite BioPharma announced that its research on novel anti-cancer drug candidate namodenoson will be featured at the 2025 ASCO Gastrointestinal Cancers Symposium. The upcoming presentation at ASCO "underscores the innovative potential" of namodenoson as both an effective anti-cancer agent and a liver-protective therapy, says the analyst, who argues that namodenoson, with "a compelling long-term case" of complete cancer remission in a Phase 2b trial patient, may represent "a paradigm shift in liver cancer therapeutics." The firm has a Buy rating and $10 price target on Can-Fite shares.
